Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan;
Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
Anticancer Res. 2022 Aug;42(8):4145-4151. doi: 10.21873/anticanres.15913.
BACKGROUND/AIM: Sulphite oxidase (SUOX) is a metalloenzyme that catalyses ATP synthesis via oxidative phosphorylation in the mitochondria. Although SUOX has been reported to affect the invasiveness and differentiation of cancer cells, its clinicopathological significance in pancreatic adenocarcinoma (PDAC) remains unclear. In this study, we investigated the utility of SUOX expression as a prognostic factor in PDAC.
This study included 56 patients with PDAC who underwent pancreatic resection at the Kurume University Hospital between 2014 and 2018. SUOX immunohistochemistry was evaluated using tissue microarray specimens from patients. Patients were classified into a high SUOX expression group (≥10% of cells stained) or a low SUOX expression group (<10% of cells stained), and the associations of SUOX with clinicopathological characteristics and survival were analysed. Statistical analysis was performed using Cox regression analysis, the Kaplan-Meier method, and log-rank test.
SUOX was expressed in the cytoplasm of normal pancreatic ductal epithelium, pancreatic acinar cells, and islets of Langerhans. Although we did not find any significant correlation between SUOX expression and clinicopathological factors, SUOX was identified as an independent prognostic factor based on univariate and multivariate analyses. Pathological stage was also an independent prognostic factor. The high SUOX expression group showed a significantly poorer prognosis than the low SUOX expression group (p=0.018).
SUOX-mediated mitochondrial metabolism in PDAC may be a factor influencing prognosis and SUOX may be a potential novel prognostic biomarker.
背景/目的：亚硫酸氧化酶（SUOX）是一种金属酶，可在线粒体中通过氧化磷酸化催化 ATP 合成。尽管已经报道 SUOX 会影响癌细胞的侵袭和分化，但它在胰腺腺癌（PDAC）中的临床病理意义尚不清楚。在本研究中，我们研究了 SUOX 表达作为 PDAC 预后因素的效用。
本研究纳入了 2014 年至 2018 年间在久留米大学医院接受胰腺切除术的 56 例 PDAC 患者。使用患者的组织微阵列标本评估 SUOX 免疫组织化学染色。将患者分为 SUOX 高表达组（≥10％的细胞染色）或 SUOX 低表达组（＜10％的细胞染色），并分析 SUOX 与临床病理特征和生存的相关性。使用 Cox 回归分析、Kaplan-Meier 方法和对数秩检验进行统计分析。
SUOX 在正常胰腺导管上皮、胰腺腺泡细胞和胰岛中表达于细胞质。尽管我们没有发现 SUOX 表达与临床病理因素之间存在任何显著相关性，但基于单因素和多因素分析，SUOX 被确定为独立的预后因素。病理分期也是独立的预后因素。SUOX 高表达组的预后明显比 SUOX 低表达组差（p=0.018）。
PDAC 中的 SUOX 介导的线粒体代谢可能是影响预后的因素，SUOX 可能是一种有前途的新型预后生物标志物。
